时间：2026年7月29日
Date: July 29, 2026
Ember联手日本药业分销巨头Alfresa锁定日本药品冷链，”资本+业务”联盟叠加Series A独家分销
Ember and Alfresa Lock In Japan Pharma Cold Chain with Capital-and-Business Alliance and Exclusive Series A Bet
摘要 :
2026年7月29日，药品冷链方案提供商Ember LifeSciences宣布与日本头部医药分销商Alfresa Corporation达成”资本+业务”联盟，Alfresa将获得Ember温控运输技术在日本医疗健康领域的独家销售权。
本次合作以Alfresa对Ember的Series A优先股投资为基础，Ember的股东阵容已包括Amgen、Cardinal Health、Carrier和Sea Court Capital。Alfresa将首先在其”居家药品配送（Home Care Delivery）”业务中试点Ember的硬件方案——包括可将温度维持在2°C至8°C且续航超过72小时并支持全程实时监控的Ember Cube 2，用于将特殊药品从医疗机构直接送达患者家中。可复用的Ember Cube被定位为传统一次性凝胶+泡沫箱的替代方案，在日本医药行业收紧ESG披露与医院加速库存合理化的背景下具有较强现实意义。双方高管将该合作视为一份”模板”，用以推动特殊生物制品在从医院向居家场景转移的过程中实现精准且可审计的温控物流。
Summary :
Ember LifeSciences, Inc., a pharmaceutical cold-chain solutions provider, announced on July 29, 2026 a capital-and-business alliance with Alfresa Corporation, Japan’s leading pharmaceutical wholesaler, giving Alfresa exclusive Japan healthcare-sector sales rights to Ember’s temperature-controlled shipping technology.
The deal is anchored by Alfresa’s Series A preferred-stock investment in Ember, joining a strategic cap table that already includes Amgen, Cardinal Health, Carrier and Sea Court Capital. Alfresa will pilot Ember’s hardware—including the Ember Cube 2, which maintains 2°C to 8°C for 72+ hours with continuous real-time monitoring—inside its Home Care Delivery service, which transports specialty medications directly from medical institutions to patients’ homes. The reusable Ember Cube design is positioned as a packaging-waste alternative to single-use gel-and-styrofoam shippers, an increasingly relevant angle as Japanese pharma tightens ESG reporting and hospitals rationalize inventory. Executives framed the tie-up as a template for bringing precision, auditable temperature control to specialty biologics logistics as more high-value therapies shift from hospitals into patients’ homes.
入选理由 :
“资金 + 独家渠道 + 市场进入试点”三合一——罕见的”三重锁定”式联盟结构，把日本出了名难攻的药品分销市场，从美国医疗科技初创企业的”高墙”直接变成”入口坡道”。
Why Selected:
“Money + exclusive channel + market-entry pilot” in one package—rare tri-lock alliance structure that turns Japan’s notoriously hard pharma-distribution market from a wall into an on-ramp for a U.S. medtech startup.
浏览量：74,500
Views：74,500
独立IP：22,800
Unique Clicks ：22,800
